NCT00668122View on ClinicalTrials.gov

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

January 31, 2006

Conditions
Urinary Tract Infection
Interventions
DRUG

Cipro XR (Ciprofloxacin, BAYQ3939)

Ciprofloxacin XR 1000 mg orally once a day

DRUG

Cipro IR (Ciprofloxacin, BAYQ3939)

Ciprofloxacin IR 500 mg orally twice a day

Trial Locations (38)

10043

Orbassano

10154

Torino

15100

Alessandria

16132

Genova

16149

Genova

20052

Monza

20132

Milan

21052

Busto Arsizio

21100

Varese

24125

Bergamo

34149

Trieste

35012

Camposampiero

36061

Bassano del Grappa

37136

Verona

40138

Bologna

42100

Reggio Emilia

46100

Mantova

47900

Rimini

50139

Florence

54100

Massa Carrara

66100

Chieti

67100

L’Aquila

70124

Bari

80131

Napoli

81100

Caserta

82100

Benevento

85100

Potenza

89124

Reggio Calabria

90129

Palermo

95124

Catania

96100

Syracuse

98165

Messina

03100

Frosinone

06122

Perugia

00144

Roma

00155

Roma

00168

Roma

07100

Sassari

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY